What is Procysbi, and what has the FDA approved?
Procysbi (delayed-release capsules of delayed-release cysteamine bitartrate) is an FDA-approved medicine used to treat patients with nephropathic cystinosis. The FDA approval covers its use in managing cystine accumulation in multiple tissues, including the kidneys, by lowering intracellular cystine. [1]
What does “FDA” mean here—approval status and labeling
When someone searches “Procysbi FDA,” they typically want the drug’s FDA status and official prescribing information. The FDA-approved labeling (package insert) is the authoritative source for approved indications, dosing instructions, contraindications, and safety information. [1]
How is Procysbi different from older cysteamine products?
Procysbi is a delayed-release formulation intended to change drug release timing compared with immediate-release cysteamine products. That formulation difference is a key part of why it has its own FDA labeling and dosing guidance. [1]
Where to find the official FDA page or prescribing information
For the most reliable details (indications, full prescribing information, warnings/precautions, and current label wording), use the FDA’s drug information entry or download the label from the FDA resource linked below. [1]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201567